Related Experiment Video

Updated: Aug 21, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

FGFR1 suppresses STING-mediated interferon response in endocrine therapy resistant breast cancer

Torbjørn Amundsen Lien1, Sushil Dhakal1, Anne Marthe Fosdahl Wium2

  • 1Oslo University Hospital Oslo, OSLO Norway.

Cancer Research Communications
|August 19, 2026
PubMed

Insights

Fibroblast growth factor receptor 1 (FGFR1) suppresses the interferon response in tamoxifen-resistant breast cancer. Inhibiting FGFR1 re-sensitizes cells to tamoxifen and enhances the interferon pathway, offering new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Fibroblast growth factor receptor 1 (FGFR1) amplification is common in ER⁺/HER2⁻ breast cancer, correlating with poor response to endocrine therapy.
  • The role of FGFR1 in regulating interferon (IFN) response during endocrine resistance is not well understood.

Purpose of the Study:

  • To investigate if FGFR1 modulates the IFN response via the cGAS-STING pathway in tamoxifen-resistant breast cancer.
  • To explore the therapeutic potential of targeting FGFR1 in overcoming endocrine resistance.

Main Methods:

  • Utilized tamoxifen-resistant ER⁺ breast cancer cell lines and a patient-derived xenograft (PDX) model.
  • Employed RNA sequencing, FGFR1 knockdown/inhibition, and functional assays.
  • Analyzed clinical relevance in breast cancer cohorts.

Main Results:

  • Tamoxifen-resistant cells showed increased cytosolic dsDNA and activated cGAS-STING pathway components (p-IRF3).
  • FGFR1 inhibition re-sensitized cells to tamoxifen, induced IFN response genes, and potentiated tamoxifen effects in vitro and in vivo.
  • FGFR1 knockdown enhanced STING-mediated IFNB1 expression in response to cytosolic DNA.
  • FGFR1 amplification correlated with poor prognosis in tumors with high STING1 expression (METABRIC cohort).

Conclusions:

  • FGFR1 acts as a suppressor of the cGAS-STING-mediated interferon response in tamoxifen-resistant ER⁺ breast cancer.
  • FGFR1's role in attenuating this response may contribute to tamoxifen resistance.
  • Targeting FGFR1 could be a novel strategy to enhance endocrine therapy efficacy.

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...